Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Mavacamten (Camzyos) is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
• The information was derived from five systematic reviews and meta-analyses studies on mavacamten's use in treating NYHA class II-III obstructive HCM.
• Statistically significant improvement in NYHA class, better health-related quality of life as measured by Kansas City Cardiomyopathy Questionnaire scores, mixed results regarding peak oxygen consumption improvements, significantly reduced left ventricular outflow tract gradient, and lower rates or eligibility for septal reduction therapy were observed with mavacamten compared to placebo.
• A slight increase in adverse events was noted without statistically significant differences in serious adverse events between mavacamten and placebo groups. Some studies reported a decrease in left ventricular ejection fraction values but no long-term safety concerns.
• Studies included patients primarily of Caucasian and Chinese ethnicity. Both obstructive (oHCM) and non-obstructive HCM types were studied, showing more pronounced effects in the obstructive subgroup. The mean age across different studies ranged approximately from 56 to 57.9 years old.
• Mavacamten shows superior efficacy over placebo concerning improving NYHA functional class and reducing LVOT gradient while being relatively well-tolerated with a manageable adverse events profile.